Carbon–carbon bond cleavage and formation reactions in drug metabolism and the role of metabolic enzymes

References

• Abel S, Russell D, Whitlock LA, et al. (2008). Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 65:60–67
   PubMed Web of Science ®Google Scholar
• Abolin CR, Tozer TN, Craig JC, et al. (1980). C-Glucuronidation of the acetylenic moiety of ethchlorvynol in the rabbit. Science 209:703–704
   PubMed Web of Science ®Google Scholar
• Ahmed AE, Trieff NM. (1983). Aliphatic nitriles: Metabolism and toxicity. Prog Drug Metab 7:229–294
   Web of Science ®Google Scholar
• Ahn SH, Duffel MW, Rosazza JP. (1997). Oxidations of vincristine catalyzed by peroxidase and ceruloplasmin. J Nat Prod 60:1125–1129
   PubMed Web of Science ®Google Scholar
• Amann T, Zenk MH. (1991). Formation of the morphine precursor salutaridine is catalyzed by a cytochrome P-450 enzyme in mammalian liver. Tetrahedron Lett 32:3675–3678
   Web of Science ®Google Scholar
• Amann T, Roos PH, Huh H, et al. (1995). Purification and characterization of a cytochrome P450 enzyme from pig liver, catalyzing the phenol oxidative coupling of (R)-reticuline to salutaridine, the critical step in porphine biosynthesis. Heterocycles 40:425–440
   Web of Science ®Google Scholar
• Argikar UA. (2012). Unusual glucuronides. Drug Metab Dispos 40:1239–1251
   PubMed Web of Science ®Google Scholar
• Askmark H, Wiholm BE. (1990). Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 81:131–140
   PubMed Web of Science ®Google Scholar
• Bershas DA, Ouellet D, Mamaril-Fishman DB, et al. (2013). Metabolism and disposition of oral dabrafenib in cancer patients: Proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidations. Drug Metab Dispos 41:2215–2224
   PubMed Web of Science ®Google Scholar
• Bolleddula J, Washington C, Colson PJ, et al. (2014a). Absorption, metabolism, and excretion of [14C]axelopran, a peripherally-restricted neutral µ-opioid receptor antagonist, after oral and intravenous administration to healthy human volunteers. 19th North American ISSX/29th JSSX meeting. San Francisco, CA, USA. Available from: http://issx.confex.com/issx/19NA/webprogrampreliminary/Paper33009.html [last accessed on 25 April 2015]
   Google Scholar
• Bolleddula J, Sullivan S, Feng L, et al. (2014b). Carbon-carbon bond cleavage and intramolecular cyclization of 2-cyanoethyl carbamate derivatives in human liver microsomes. 19th North American ISSX/29th JSSX meeting. San Francisco, CA, USA. Available from: http://issx.confex.com/issx/19NA/webprogrampreliminary/Paper33175.html [last accessed on 25 April 2015]
   Google Scholar
• Bolleddula J, DeMent K, Driscoll JP, et al. (2014c). Biotransformation and bioactivation reactions of alicyclic amines in drug molecules. Drug Metab Rev 46:379–419
   PubMed Web of Science ®Google Scholar
• Borel AG, Jones TM, Barbuch RJ, et al. (2011). Metabolism of LY654322, a growth hormone secretagogue, to an unusual diimidazopyridine metabolite. Drug Metab Dispos 39:740–749
   PubMed Web of Science ®Google Scholar
• Brandon EFA, Sparidans RF, Van Ooijen RD, et al. (2006). In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs 25:9–19
   Web of Science ®Google Scholar
• Cada DJ, Demaris K, Levien TL, et al. (2013). Tofacitinib. Hosp Pharm 48:413–424
   PubMedGoogle Scholar
• Cazzola M, Page CP, Calzetta L, et al. (2012). Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 64:450–504
   PubMed Web of Science ®Google Scholar
• Chen GP, Poulsen LL, and Ziegler DM. (1995). Oxidation of aldehydes catalyzed by pig liver flavin-containing monooxygenase. Drug Metab Dispos 23:1390–1393
   PubMed Web of Science ®Google Scholar
• Chen H, Shockcor J, Chen W, et al. (2002). Delineating novel metabolic pathways of DPC 963, a non-nucleoside reverse transcriptase inhibitor, in rats. Characterization of glutathione conjugates of postulated oxirene and benzoquinone imine intermediates by LC/MS and LC/NMR. Chem Res Toxicol 15:388–399
   PubMed Web of Science ®Google Scholar
• Chen H, Chen W, Gan LS, et al. (2003). Metabolism of (s)-5,6-difluoro-4-cyclopropylethynyl-4-trifluoromethyl-3, 4-dihydro-2(1h)-quinazolinone, a non-nucleoside reverse transcriptase inhibitor, in human liver microsomes. Metabolic activation and enzyme kinetics. Drug Metab Dispos 31:122–132
   PubMed Web of Science ®Google Scholar
• Corina DL, Miller SL, Wright JN, et al. (1991). The mechanism of cytochrome P-450 dependent C–C bond cleavage: Studies on 17a-hydroxylase-17,20-lyase. J Chem Soc Chem Commun 1991:782–783
   Google Scholar
• Coulet M, Eeckhoutte C, Larrieu G, et al. (2000). Evidence for cytochrome P4501A2 mediated protein covalent binding of thiabendazole and for its passive intestinal transport: Use of human and rabbit derived cells. Chem Biol Interact 127:109–124
   PubMed Web of Science ®Google Scholar
• Dahl SL. (1993). Nabumetone: A “nonacidic” non-steroidal anti-inflammatory drug. Ann Pharmacother 27:456–463
   PubMed Web of Science ®Google Scholar
• Dalvie D, Smith E, Deese A, et al. (2006). In vitro metabolic activation of thiabendazole via 5-hydroxythiabendazole: Identification of a glutathione conjugate of 5-hydroxythiabendazole. Drug Metab Dispos 34:709–717
   PubMed Web of Science ®Google Scholar
• Dalvie D, Chen W, Zhang C, et al. (2008). Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos 36:2185–2198
   PubMed Web of Science ®Google Scholar
• Dennison JB, Kulanthaivel P, Barbuch RJ, et al. (2006). Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317–1327
   PubMed Web of Science ®Google Scholar
• Dewick PM. (2002). Medicinal natural products: A biosynthetic approach. 2nd ed. West Sussex, England: John Wiley & Sons Ltd
   Google Scholar
• Dowty ME, Lin J, Ryder TF, et al. (2014). The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos 42:759–773
   PubMed Web of Science ®Google Scholar
• Doyon L, Tremblay S, Bourgon L, et al. (2005). Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res 68:27–35
   PubMed Web of Science ®Google Scholar
• Empey DW, Laitinen LA, Young GA, et al. (1979). Comparison of the antitussive effects of codeine phosphate 20 mg, dextromethorphan 30 mg and noscapine 30 mg using citric acid-induced cough in normal subjects. Eur J Clin Pharmacol 16:393–397
   PubMed Web of Science ®Google Scholar
• Escudier B, Gore M. (2011). Axitinib for the management of metastatic renal cell carcinoma. Drugs R& D 11:113–126
   PubMedGoogle Scholar
• Faircloth G, Hanauske A, Depenbrock H, et al. (1997). Pre-clinical characterization of aplidine, a new marine anticancer depsipeptide. Proc Am Assoc Cancer Res 38:692
   Google Scholar
• Fang ZZ, Krausz KW, Li F, et al. (2012). Metabolic map and bioactivation of the anti-tumour drug noscapine. Br J Pharmacol 167:1271–1286
   PubMed Web of Science ®Google Scholar
• Furst SM, Uetrecht JP. (1993). Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem Pharmacol 45:1267–1275
   PubMed Web of Science ®Google Scholar
• Gong YD, Cho H, Jeon MK, et al. (2009). Novel 2,4,5-trisubstituted-1,3-thiazole derivatives and pharmaceutically acceptable salt thereof, method for preparation, therapeutic agent for inflammatory disease induced by SPC activity containing 2,4,5-trisubstituted-1,3-thiazole derivatives as an effective ingredient. International patent WO2009041790
   Google Scholar
• Goswami A, Macdonald TL, Hubbard C, et al. (1988). Leurosine biotransformations: An unusual ring-fission reaction catalyzed by peroxidase. Chem Res Toxicol 1:238–242
   PubMed Web of Science ®Google Scholar
• Groten JP, Butler W, Feron VJ, et al. (2000). An analysis of the possibility for health implications of joint actions and interactions between food additives. Reg Toxicol Pharmacol 31:77–91
   PubMed Web of Science ®Google Scholar
• Guengerich PF. (2001). Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611–650
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (2007). Mechanisms of cytochrome P450 substrate oxidation: Minireview. J Biochem Mol Toxicol 21:163–168
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Rendic S. (2010). Update information on drug metabolism systems-2009, Part I. Curr Drug Metab 11:1–3
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Isin EM. (2014). Unusual metabolic reactions and pathways. In: Lee P, Aizawa H, Gan L, et al., eds. Handbook of metabolic pathways of xenobiotics. Hoboken: John Wiley & Sons, Inc., 147–191
   Google Scholar
• Ha-Duong NT, Dijols S, Macherey AC, et al. (2001). Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40:12112–12122
   PubMed Web of Science ®Google Scholar
• Harrell AW, Siederer SK, Bal J, et al. (2013). Metabolism and disposition of vilanterol, a long-acting β2-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos 41:89–100
   PubMed Web of Science ®Google Scholar
• Haruda F. (1979). Phenytoin hypersensitivity: 38 cases. Neurology 29:1480–1485
   PubMed Web of Science ®Google Scholar
• Harvey DJ, Paton WD. (1980). Identification of in vivo liver metabolites of delta 6-tetrahydrocannabinol produced by the mouse. Drug Metab Dispos 8:178–186
   PubMed Web of Science ®Google Scholar
• Harvey DJ, Leuschner JTA. (1985). Studies on the β-oxidative metabolism of D1- and D6-tetrahydrocannabinol in the mouse. Drug Metab Dispos 13:215–219
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomized controlled trial. Lancet 380:358–365
   PubMed Web of Science ®Google Scholar
• He H, Tran P, Yin H, et al. (2009). Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 37:536–544
   PubMed Web of Science ®Google Scholar
• Hedner T, Samulesson O, Währborg P, et al. (2004). Nabumetone: Therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs 64:2315–2343
   PubMed Web of Science ®Google Scholar
• Howes LG, Kostner K. (2007). The withdrawal of torcetrapib from drug development: Implications for the future of drugs that alter HDL metabolism. Expert Opin Investig Drugs 16:1509–1516
   PubMed Web of Science ®Google Scholar
• Jacobson AK. (2004). Platelet ADP receptor antagonists: Ticlopidine and clopidogrel. Best Pract Res Clin Haematol 17:55–64
   PubMed Web of Science ®Google Scholar
• Meng J, Zhong D, Li L, et al. (2015). Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: The oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes. Drug Metab Dispos 43:646–659
   PubMed Web of Science ®Google Scholar
• Kagan M, Dain J, Peng L, Reynolds C. (2012). Metabolism and pharmacokinetics of indacaterol in humans. Drug Metab Dispos 40:1712–1722
   PubMed Web of Science ®Google Scholar
• Kaplita PV, Smith RP. (1986). Pathways for the bioactivation of aliphatic nitriles to free cyanide in mice. Toxicol Appl Pharmacol 84:533–540
   PubMed Web of Science ®Google Scholar
• Karha J, Cannon CP. (2008). ADP receptor antagonists. In: Bhat LD, ed. Platelets in cardiovascular disease. London: Imperial College Press, 87–124
   Google Scholar
• Kerdpin O, Elliot DJ, Mackenzie PI, et al. (2006). Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9. Drug Metab Dispos 34:1950–1953
   PubMed Web of Science ®Google Scholar
• Kudo S, Umehara K, Morita S, et al. (1998a). Metabolism of 1-(3,4-dichlorobenzyl)-5-octylbiguanide in the dog. Xenobiotica 28:507–514
   PubMed Web of Science ®Google Scholar
• Kudo S, Umehara K, Odomi M, et al. (1998b). Metabolism of a new bactericidal antiseptic, OPB-2045, in rats following subcutaneous administration. Drug Metab Dispos 13:346–350
   Google Scholar
• Lai WG, Farah N, Moniz GA, et al. (2011). A Baeyer–Villiger oxidation specifically catalyzed by human flavin-containing monooxygenase 5. Drug Metab Dispos 39:61–70
   PubMed Web of Science ®Google Scholar
• Lawrence SK, Nguyen D, Bowen D, et al. (2014). The metabolic drug-drug interaction profile of dabrafenib: In vitro investigations and quantitative extrapolation of the P450-mediated DDI risk. Drug Metab Dispos 42:1180–1190
   PubMed Web of Science ®Google Scholar
• Li F, Gonzalez FJ, Ma X. (2012). LC–MS-based metabolomics in profiling of drug metabolism and bioactivation. Acta Pharm Sin B 2:116–123
   Google Scholar
• Lu W, Uetrecht JP. (2008). Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin. Drug Metab Dispos 36:1624–1636
   PubMed Web of Science ®Google Scholar
• Mackenzie PI, Bock KW, Burchell B, et al. (2005). Nomenclatures update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677–685
   PubMed Web of Science ®Google Scholar
• Mahmoudian M, Mehrpour M, Benaissa F, et al. (2003). A preliminary report on the application of noscapine in the treatment of stroke. Eur J Clin Pharmacol 59:579–581
   PubMed Web of Science ®Google Scholar
• Mahmoudian M, Rahimi-Moghaddam P. (2009). The anti-cancer activity of noscapine: A review. Recent Pat Anti-Cancer Drug Discov 4:92–97
   PubMed Web of Science ®Google Scholar
• Miller SL, Wright JN, Corina DL, et al. (1991). Mechanistic studies on pregneneside-chain cleavage enzyme (17a-hydroxylase-17,20-lyase) using 18O. J Chem Soc Chem Commun 1991:157–159
   Google Scholar
• Mizutani T, Ito K, Nomura H, et al. (1990). Nephrotoxicity of thiabendazole in mice depleted of glutathione by treatment with DL-buthionine sulphoximine. Food Chem Toxicol 28:169–177
   PubMed Web of Science ®Google Scholar
• Mizutani M, Sato F. (2011). Unusual P450 reactions in plant secondary metabolism. Arch Biochem Biophys 507:194–203
   PubMed Web of Science ®Google Scholar
• Nishiyama T, Kobori T, Arai K, et al. (2006). Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone. Arch Biochem Biophys 454:72–79
   PubMed Web of Science ®Google Scholar
• Ogata A, Ando H, Kubo Y, et al. (1984). Teratogenicity of thiabendazole in ICR mice. Food Chem Toxicol 22:509–520
   PubMed Web of Science ®Google Scholar
• Orlikova B, Legrand N, Panning J, et al. (2014). Anti-inflammatory and anticancer drugs from nature. Cancer Treat Res 159:123–143
   PubMedGoogle Scholar
• Ortiz de Montellano PR. (ed.) (1995). Oxygen activation and reactivity, in cytochrome P450: Structure, mechanism, and biochemistry. 2nd ed. New York: Plenum Press, 245–303
   Google Scholar
• Ortiz de Montellano PR, De Voss JJ. (2005). Substrate oxidation by cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450: Structure, Mechanism, and Biochemistry. 3rd ed. New York: Kluwer Academic/Plenum Publishers, 183–245
   Google Scholar
• Ortiz de Montellano PR, Nelson SD. (2011). Rearrangement reactions catalyzed by cytochrome P450s. Arch Biochem Biophys 507: 95–110
   PubMed Web of Science ®Google Scholar
• Panina G. (2007). The DPP-4 inhibitor vildagliptin: Robust glycemic control in type 2 diabetes and beyond. Diabetes Obes Metab 9 Suppl 1:32–39
   Web of Science ®Google Scholar
• Paralkar VM, Borovecki F, Ke HZ, et al. (2003). An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Nat Acad Sci USA 100:6736–6740
   PubMed Web of Science ®Google Scholar
• Pearce RE, Vakkalagadda GR, Leeder JS. (2002). Pathways of carbamazepine bioactivation in vitro I. characterization of human cytochromes p450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos 30:1170–1179
   PubMed Web of Science ®Google Scholar
• Penner NA, Ho G, Bercovici A, Chowdhury SK, Alton KB. (2010). Identification of two novel metabolites of SCH 486757, a nociceptin/orphanin FQ peptide receptor agonist, in humans. Drug Metab Dispos 38:2067–2074
   PubMed Web of Science ®Google Scholar
• Penner N, Woodward C, Prakash C. (2012). Drug metabolizing enzymes and biotransformation reactions. In: Zhang D, Surapaneni S, ed. ADME-Enabling technologies in drug design and development. Hoboken: John Wiley & Sons, Inc., 545–565
   Google Scholar
• Prakash C, Chen W, Rossulek M, et al. (2008). Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: Characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance. Drug Metab Dispos 36:2064–2079
   PubMed Web of Science ®Google Scholar
• Rieger RA, Hinkin RJ, Robinson J, et al. (2013). Dual carbon-carbon bond breaking metabolism in an alkyl nitrile-containing xenobiotic by rHuCYP1A2 and associated metabolite and biomarker monitoring in preclinical species. 18th International Conference on Cytochrome P450). Abstract #47
   Google Scholar
• Roberts ES, Vaz AD, Coon MJ. (1991). Catalysis by cytochrome P-450 of an oxidative reaction in xenobiotic aldehyde metabolism: Deformylation with olefin formation. Proc Natl Acad Sci USA 88:8963–8966
   PubMed Web of Science ®Google Scholar
• Shimizu S, Atsumi R, Nakazawa T, et al. (2009). Metabolism of ticlopidine in rats: Identification of the main biliary metabolite as a glutathione conjugate of ticlopidine S-oxide. Drug Metab Dispos 37:1904–1915
   PubMed Web of Science ®Google Scholar
• Sinz MW, Black AE, Bjorge SM, et al. (1997). In vitro and in vivo disposition of 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide (CI-976). Drug Metab Dispos 25:123–130
   PubMed Web of Science ®Google Scholar
• Smith BJ, Pithavala Y, Bu HZ, et al. (2014). Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans. Drug Metab Dispos 42:918–931
   PubMed Web of Science ®Google Scholar
• Song M, Lee D, Kim S, et al. (2014). Identification of metabolites of N-(5-Benzoyl-2-(4-(2-Methoxyphenyl) piperazin-1-yl)thiazol-4-yl)pivalamide Including CYP3A4-mediated C-demethylation in human liver microsomes with high-resolution/high-accuracy tandem masss. Drug Metab Dispos 42:1252–1260
   PubMed Web of Science ®Google Scholar
• Talakad JC, Shah MB, Walker GS, et al. (2011). Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4. Drug Metab Dispos 39:539–550
   PubMed Web of Science ®Google Scholar
• Tocco DJ, Rosenblum C, Martin CM, et al. (1966). Absorption, metabolism and excretion of thiabendazole in man and laboratory animals. Toxicol Appl Pharmacol 9:31–39
   PubMed Web of Science ®Google Scholar
• Treiber A, Dansette PM, el Amri H, et al. (1997). Chemical and biological oxidation of thiophene: Preparation and complete characterization of thiophene S-oxide dimers and evidence for thiophene S-oxide as an intermediate in thiophene metabolism in vivo and in vitro. J Am Chem Soc 119:1565–1571
   Web of Science ®Google Scholar
• Tsunoda N, Yoshimura H. (1979). Metabolic fate of noscapine II. Isolation and identification of novel metabolites produce by C–C bond cleavage. Xenobiotica 9:181–187
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Hofmann U, Klein K, et al. (2009). A Predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos 37:1017–1024
   PubMed Web of Science ®Google Scholar
• Uetrecht J, Naisbitt DJ. (2013). Idiosyncratic adverse drug reactions: Current concepts. Pharmacol Rev 65:779–808
   PubMed Web of Science ®Google Scholar
• Umehara K, Kudo S, Hirao Y, et al. (2000a). In vitro characterization of the oxidative cleavage of the octyl side chain of olanexidine, a novel antimicrobial agent, in dog liver microsomes. Drug Metab Dispos 28:1417–1424
   PubMed Web of Science ®Google Scholar
• Umehara K, Kudo S, Hirao Y, et al. (2000b). Oxidative cleavage of the octyl side chain of 1-(3,4-dichlorobenzyl)-5-octylbiguanide (opb-2045) in rat and dog liver preparations. Drug Metab Dispos 28:887–894
   PubMed Web of Science ®Google Scholar
• Varfaj F, Zifli SNA, Park HG, et al. (2014). Carbon-carbon bond cleavage in activation of the prodrug nabumetones. Drug Metab Dispos 42:828–838
   PubMed Web of Science ®Google Scholar
• Vaz AD. (2001). Multiple oxidants in cytochrome P450 catalyzed reactions: Implications for drug metabolism. Curr Drug Metab 2:1–16
   PubMed Web of Science ®Google Scholar
• Verhoeven CHJ, Krebbers SFM, Wagenaars GN, et al. (1998). In vitro and in vivo metabolism of the progestagen org 30659 in several species. Drug Metab Dispos 26:1102–1112
   PubMed Web of Science ®Google Scholar
• Walton K, Walker R, van de Sandt JJM, et al. (1999). The application of in vitro data in the derivation of the acceptable daily intake of food additives. Food Chem Toxicol 37:1175–1197
   PubMed Web of Science ®Google Scholar
• Woodcock A, McLeod RL, Sadeh J, et al. (2010). The efficacy of a NOP1 agonist (SCH486757) in subacute cough. Lung 188 (Suppl 1):S47–52
   Google Scholar
• Yamaguchi H, Kubo J, Sekine K, et al. (1979). Metabolites of feprazone in man. Drug Metab Dispos 7:340–344
   PubMed Web of Science ®Google Scholar
• Yin W, Doss GA, Stearns RA, et al. (2003). A novel P450-catalyzed transformation of the 2,2,6,6-tetramethyl piperidine moiety to a 2,2-dimethyl pyrrolidine in human liver microsomes: Characterization by high resolution quadrupole-time-offlight mass spectrometry and 1H NMR. Drug Metab Dispos 31:215–223
   PubMed Web of Science ®Google Scholar
• Yin W, Mitra K, Stearns RA, et al. (2004). Conversion of the 2, 2, 6, 6-tetramethylpiperidine moiety to a 2,2-dimethylpyrrolidine by cytochrome P450: Evidence for a mechanism involving nitroxide radicals and heme iron. Biochem 43:5455–5466
   PubMed Web of Science ®Google Scholar
• Yoo HH, Chung HJ, Lee J, et al. (2008). Enzymatic C-demethylation of 1-[2-(5-tert-Butyl-[1,3,4] oxadiazole-2-carbonyl)-4-fluoro-pyrrolidin-1-yl]-2-(2-hydroxy-1,1-dimethylethylamino)-ethanone (LC15-0133) in rat liver microsomes. Drug Metab Dispos 36:485–489
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen Q, Li Y, et al. (2005). In vitro bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: Formation of reactive iminium and quinone type metabolites. Chem Res Toxicol 18:675–685
   PubMed Web of Science ®Google Scholar
• Zhao ZY, Leung LY, Trevor A, et al. (1991). C-Formylation in the presence of rat brain mitochondria of the 2, 3, 4, 5-tetrahydropyridinium metabolite derived from the psychotomimetic drug phencyclidine. Chem Res Toxicol 4:426–429
   PubMed Web of Science ®Google Scholar